PERSPECTIVE FOR APPLYING ANTITUMOR VACCINES

Abstract

One of the promising areas in immunotherapy are tumour-specific vaccines based on immunocompromised cells. DC-based personalized neoantigenic cellular vaccines have promising antitumor effects in clinical practice. Dendritic cell-based vaccines have a number of advantages, one example being the ability to engage both innate and adaptive immunity, as well as to develop long-term immunological memory against tumor recurrence. DCs are the most professional and consistent antigens and are more effective in activating resting T cells. The review provides the most up-to-date information on cancer vaccines, as well as an analysis of the types of cancer vaccines from domestic and foreign sources. The conclusion of this brief review is the wide variety of types of tumor-specific vaccines and their rapid improvement.